These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 14583458

  • 1. Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4.
    Ito Y, Oike Y, Yasunaga K, Hamada K, Miyata K, Matsumoto S, Sugano S, Tanihara H, Masuho Y, Suda T.
    Cancer Res; 2003 Oct 15; 63(20):6651-7. PubMed ID: 14583458
    [Abstract] [Full Text] [Related]

  • 2. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J.
    Mol Cancer Res; 2002 Nov 15; 1(1):2-11. PubMed ID: 12496364
    [Abstract] [Full Text] [Related]

  • 3. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.
    He GA, Luo JX, Zhang TY, Hu ZS, Wang FY.
    Biochem Biophys Res Commun; 2004 May 28; 318(2):354-60. PubMed ID: 15120609
    [Abstract] [Full Text] [Related]

  • 4. Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties.
    Dhanabal M, LaRochelle WJ, Jeffers M, Herrmann J, Rastelli L, McDonald WF, Chillakuru RA, Yang M, Boldog FL, Padigaru M, McQueeney KD, Wu F, Minskoff SA, Shimkets RA, Lichenstein HS.
    Cancer Res; 2002 Jul 01; 62(13):3834-41. PubMed ID: 12097297
    [Abstract] [Full Text] [Related]

  • 5. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.
    Cancer Res; 2004 May 15; 64(10):3586-92. PubMed ID: 15150116
    [Abstract] [Full Text] [Related]

  • 6. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
    Hagedorn M, Zilberberg L, Wilting J, Canron X, Carrabba G, Giussani C, Pluderi M, Bello L, Bikfalvi A.
    Cancer Res; 2002 Dec 01; 62(23):6884-90. PubMed ID: 12460903
    [Abstract] [Full Text] [Related]

  • 7. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
    Morbidelli L, Donnini S, Chillemi F, Giachetti A, Ziche M.
    Clin Cancer Res; 2003 Nov 01; 9(14):5358-69. PubMed ID: 14614021
    [Abstract] [Full Text] [Related]

  • 8. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 9. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis.
    Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S, Karpatkin S.
    Cancer Res; 2006 Apr 15; 66(8):4125-32. PubMed ID: 16618733
    [Abstract] [Full Text] [Related]

  • 10. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
    Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM.
    Nat Med; 2003 Aug 15; 9(8):1026-32. PubMed ID: 12872165
    [Abstract] [Full Text] [Related]

  • 11. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.
    Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, Mumm JB, Stewart AL, Boquoi A, Dumoutier L, Grimm EA, Renauld JC, Kotenko S, Chada S.
    Cancer Res; 2003 Aug 15; 63(16):5105-13. PubMed ID: 12941841
    [Abstract] [Full Text] [Related]

  • 12. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S, Sellers LA, Cindrova T, Skepper J, Gherardi E, Sasisekharan R, Fan TP.
    Cancer Res; 2003 Dec 01; 63(23):8351-9. PubMed ID: 14678996
    [Abstract] [Full Text] [Related]

  • 13. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R.
    Cancer Res; 2004 Sep 15; 64(18):6626-34. PubMed ID: 15374977
    [Abstract] [Full Text] [Related]

  • 14. Evidence of human thrombomodulin domain as a novel angiogenic factor.
    Shi CS, Shi GY, Chang YS, Han HS, Kuo CH, Liu C, Huang HC, Chang YJ, Chen PS, Wu HL.
    Circulation; 2005 Apr 05; 111(13):1627-36. PubMed ID: 15795324
    [Abstract] [Full Text] [Related]

  • 15. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG, Kim TD, Li G, Yoon WH, Chae CB.
    Clin Cancer Res; 2005 Apr 01; 11(7):2651-61. PubMed ID: 15814646
    [Abstract] [Full Text] [Related]

  • 16. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y, Wang S, Hoot DR, Clinton SK.
    J Nutr Biochem; 2007 Jun 01; 18(6):408-17. PubMed ID: 17142033
    [Abstract] [Full Text] [Related]

  • 17. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
    Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY, Davis PJ.
    Angiogenesis; 2008 Jun 01; 11(2):183-90. PubMed ID: 18080776
    [Abstract] [Full Text] [Related]

  • 18. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth.
    Ueda Y, Yamagishi T, Samata K, Ikeya H, Hirayama N, Okazaki T, Nishihara S, Arai K, Yamaguchi S, Shibuya M, Nakaike S, Tanaka M.
    Cancer Chemother Pharmacol; 2004 Jul 01; 54(1):16-24. PubMed ID: 15064856
    [Abstract] [Full Text] [Related]

  • 19. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.
    Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, Zhang JC, Rabbani SA, McCrae KR, Mazar AP, Morgan WT, Doñate F.
    Cancer Res; 2002 Sep 15; 62(18):5344-50. PubMed ID: 12235005
    [Abstract] [Full Text] [Related]

  • 20. Thymosin {beta}(10) inhibits angiogenesis and tumor growth by interfering with Ras function.
    Lee SH, Son MJ, Oh SH, Rho SB, Park K, Kim YJ, Park MS, Lee JH.
    Cancer Res; 2005 Jan 01; 65(1):137-48. PubMed ID: 15665289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.